Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte

Objectives Clinical studies have indicated the beneficial effect of an L/N-type calcium channel blocker (CCB), cilnidipine, on the progression of proteinuria in hypertensive patients compared with an L-type CCB, amlodipine. In the present study, we examined the effects of cilnidipine and amlodipine on the renal injury in spontaneously hypertensive rat/ND mcr-cp (SHR/ND) and their underlying mechanism. Methods and results SHR/ND were treated with vehicle (n = 10), cilnidipine [33 mg/kg per day, orally (p.o.); n = 11] or amlodipine (20 mg/kg per day, p.o.; n = 9) for 20 weeks. SHR/ND developed proteinuria in an age-dependent manner. Cilnidipine suppressed the proteinuria greater than amlodipine did. The immunohistochemical analysis showed that N-type calcium channel and Wilm's tumor factor, a marker of podocyte, were co-expressed. SHR/ND had significantly greater desmin staining, an indicator of podocyte injury, with lower podocin and nephrin expression in the glomeruli than Wistar–Kyoto rat or SHR. Cilnidipine significantly prevented the increase in desmin staining and restored the glomerular podocin and nephrin expression compared with amlodipine. Cilnidipine also prevented the increase in renal angiotensin II content, the expression and membrane translocation of NADPH oxidase subunits and dihydroethidium staining in SHR/ND. In contrast, amlodipine failed to change these renal parameters. Conclusion These data suggest that cilnidipine suppressed the development of proteinuria greater than amlodipine possibly through inhibiting N-type calcium channel-dependent podocyte injury in SHR/ND.

[1]  P. Bie,et al.  Renin secretion and total body sodium: Pathways of integrative control , 2010, Clinical and experimental pharmacology & physiology.

[2]  T. Fujita,et al.  Comparison of antioxidant activity of cilnidipine and amlodipine. , 2009, Kidney International.

[3]  K. Nitta,et al.  Different Effects of L/N-Type and L-Type Calcium Channel Blockers on the Renin-Angiotensin-Aldosterone System in SHR/Izm , 2009, American Journal of Nephrology.

[4]  J. Ingelfinger,et al.  Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension. , 2009, Kidney international.

[5]  W. Comper,et al.  Disease-dependent mechanisms of albuminuria. , 2008, American journal of physiology. Renal physiology.

[6]  K. Kimura,et al.  Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. , 2008, International heart journal.

[7]  Takashi Suzuki,et al.  Modified Sympathetic Nerve System Activity with Overexpression of the Voltage-dependent Calcium Channel β3 Subunit* , 2008, Journal of Biological Chemistry.

[8]  H. Pavenstädt,et al.  Mechanisms of angiotensin II signaling on cytoskeleton of podocytes , 2008, Journal of Molecular Medicine.

[9]  S. Ito,et al.  Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria , 2008, Journal of hypertension.

[10]  H. Yokoi,et al.  Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. , 2008, Kidney international.

[11]  V. Demarco,et al.  Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin Treatment , 2008, Hypertension.

[12]  J. Ingelfinger,et al.  Overexpression of angiotensinogen increases tubular apoptosis in diabetes. , 2008, Journal of the American Society of Nephrology : JASN.

[13]  G. Yasuda,et al.  Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. , 2007, Kidney international.

[14]  N. Vaziri,et al.  Intra-Renal Angiotensin II/AT1 Receptor, Oxidative Stress, Inflammation, and Progressive Injury in Renal Mass Reduction , 2007, Journal of Pharmacology and Experimental Therapeutics.

[15]  T. Iwasaka,et al.  Renal and vascular protective effects of cilnidipine in patients with essential hypertension , 2007, Journal of hypertension.

[16]  J. Ingelfinger,et al.  Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. , 2007, Kidney international.

[17]  K. Kario,et al.  The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. , 2007, American journal of hypertension.

[18]  K. Homma,et al.  Ca2+ channel subtypes and pharmacology in the kidney. , 2007, Circulation research.

[19]  V. Cachofeiro,et al.  Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. , 2006, Journal of the American Society of Nephrology : JASN.

[20]  W. Atchison,et al.  Acetylcholine Release at Neuromuscular Junctions of Adult Tottering Mice Is Controlled by N-(Cav2.2) and R-Type (Cav2.3) but Not L-Type (Cav1.2) Ca2+ Channels , 2006, Journal of Pharmacology and Experimental Therapeutics.

[21]  A. Nishiyama,et al.  Effects of Adrenomedullin on Cardiac Oxidative Stress and Collagen Accumulation in Aldosterone-Dependent Malignant Hypertensive Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[22]  D. Ekuni,et al.  Regulation of epithelial cell growth factor receptor protein and gene expression using a rat periodontitis model. , 2006, Journal of periodontal research.

[23]  Hiroshi Yamamoto,et al.  Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. , 2006, Biological & pharmaceutical bulletin.

[24]  A. Nishiyama,et al.  D-allose, an all-cis aldo-hexose, suppresses development of salt-induced hypertension in Dahl rats , 2005, Journal of hypertension.

[25]  T. Moriyama,et al.  The N- and L-Type Calcium Channel Blocker Cilnidipine Suppresses Renal Injury in Dahl Rats Fed a High-Sucrose Diet, an Experimental Model of Metabolic Syndrome , 2005, Nephron Physiology.

[26]  H. Kobori,et al.  Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. , 2005, Journal of the American Society of Nephrology : JASN.

[27]  G. Chertow,et al.  Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. , 2005, Journal of the American Society of Nephrology : JASN.

[28]  H. Kobori,et al.  Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. , 2005, Journal of the American Society of Nephrology : JASN.

[29]  I. G. Fantus,et al.  Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells. , 2004, The Journal of endocrinology.

[30]  P. Whelton,et al.  Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). , 2004, Annals of epidemiology.

[31]  H. Yokoyama,et al.  Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[32]  Katrin Rittinger,et al.  Molecular Basis of Phosphorylation-Induced Activation of the NADPH Oxidase , 2003, Cell.

[33]  A. Shah,et al.  Intracellular Localization and Preassembly of the NADPH Oxidase Complex in Cultured Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[34]  E. Frohlich,et al.  N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model , 2002, Journal of hypertension.

[35]  L. Cebotaru,et al.  Tubular and cellular localization of the cardiac L-type calcium channel in rat kidney. , 2002, Kidney international.

[36]  E. Frohlich,et al.  Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen , 2002, Journal of hypertension.

[37]  H. Suzuki,et al.  Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.

[38]  H. Pavenstädt,et al.  Acetylcholine increases the free intracellular calcium concentration in podocytes in intact rat glomeruli via muscarinic M(5) receptors. , 2001, Journal of the American Society of Nephrology : JASN.

[39]  S. Nielsen,et al.  The alpha(1G)-subunit of a voltage-dependent Ca(2+) channel is localized in rat distal nephron and collecting duct. , 2000, American journal of physiology. Renal physiology.

[40]  J. Gloy,et al.  Catecholamines modulate podocyte function. , 1998, Journal of the American Society of Nephrology : JASN.

[41]  R. Zeller,et al.  Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. , 1997, Experimental cell research.

[42]  Maristela L Onozato,et al.  Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. , 2002, Kidney international.

[43]  G. Shearer,et al.  Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. , 2001, Kidney international.

[44]  J. Gloy,et al.  Angiotensin II increases the intracellular calcium activity in podocytes of the intact glomerulus. , 2000, Kidney international.